Overall, our results suggest that strategies to interfere with the Src and IGF-1R pathways in PCa are effective and that using small tyrosine-kinase inhibitors (TKIs) against both targets is more potent than specific targeting, likely reflecting inhibition of related targets by the TKIs. The gene discussed is SRC; the disease is posterior cortical atrophy.